表紙
市場調査レポート

消化管運動障害:パイプライン製品の分析

Gastric Motility Disorder - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 253664
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
消化管運動障害:パイプライン製品の分析 Gastric Motility Disorder - Pipeline Review, H2 2014
出版日: 2014年09月10日 ページ情報: 英文 37 Pages
概要

消化管運動障害の症状には、慢性的な嘔吐、悪心、痙攣、膨満感、胸やけ、腹部膨張、食後の下痢などがあります。

当レポートでは、消化管運動障害治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

消化管運動障害の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

消化管運動障害:企業で開発中の治療薬

消化管運動障害:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

消化管運動障害:企業で開発中の製品

消化管運動障害の治療薬開発に従事している企業

  • Theravance, Inc.
  • Helsinn Healthcare S.A.
  • Concert Pharmaceuticals, Inc.
  • Targacept, Inc.
  • ChironWells GmbH

消化管運動障害:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • velusetrag
  • ipamorelin
  • TD-8954
  • TC-6499
  • 小分子

消化管運動障害:最近のパイプライン動向

消化管運動障害:休止中のプロジェクト

消化管運動障害:開発が中止された製品

消化管運動障害:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5521IDB

Summary

Global Markets Direct's, 'Gastric Motility Disorder - Pipeline Review, H2 2014', provides an overview of the Gastric Motility Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Motility Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Motility Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastric Motility Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastric Motility Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastric Motility Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastric Motility Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastric Motility Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastric Motility Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Gastric Motility Disorder - Overview
    • Pipeline Products for Gastric Motility Disorder - Comparative Analysis
  • Gastric Motility Disorder - Therapeutics under Development by Companies
  • Gastric Motility Disorder - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gastric Motility Disorder - Products under Development by Companies
  • Gastric Motility Disorder - Companies Involved in Therapeutics Development
    • Helsinn Healthcare S.A.
    • Targacept, Inc.
    • ChironWells GmbH
  • Gastric Motility Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • velusetrag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipamorelin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TD-8954 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TC-6499 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Bowel Motility Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastric Motility Disorder - Recent Pipeline Updates
  • Gastric Motility Disorder - Dormant Projects
  • Gastric Motility Disorder - Discontinued Products
  • Gastric Motility Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2012: RaQualia Pharma Initiates First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
      • Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastric Motility Disorder, H2 2014
  • Number of Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Gastric Motility Disorder - Pipeline by Helsinn Healthcare S.A., H2 2014
  • Gastric Motility Disorder - Pipeline by Targacept, Inc., H2 2014
  • Gastric Motility Disorder - Pipeline by ChironWells GmbH, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Gastric Motility Disorder Therapeutics - Recent Pipeline Updates, H2 2014
  • Gastric Motility Disorder - Dormant Projects, H2 2014
  • Gastric Motility Disorder - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Gastric Motility Disorder, H2 2014
  • Number of Products under Development for Gastric Motility Disorder - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top